Multicenter prospective observational study of dupilumab‐induced ocular events in atopic dermatitis patients
Ingrid Costedoat
(1)
,
Martin Wallaert
(2)
,
Aurelie Gaultier
(3, 4)
,
Robin Vasseur
(2)
,
Clelia Vanhaecke
(5)
,
Manuelle Viguier
(6)
,
Charles Cordelette
(7)
,
Alexandre Denoyer
(8)
,
Marie‐christine Ferrier Le Bouëdec
(9)
,
Adrien Coutu
(10)
,
Marie Lamiaux
,
Thi Ha Châu Tran
(11)
,
Jean Philippe Lacour
(12)
,
Valerie Elmaleh
(13)
,
Florence Tetart
(14, 15)
,
Julie Gueudry
(16, 17)
,
Marie Tauber
(18)
,
Francoise Giordano-Labadie
(19)
,
Myriam Cassagne
(19, 18)
,
Audrey Nosbaum
(20)
,
Coralie Ouilhon
(21)
,
Marie Jachiet
(22)
,
Ramin Tadayoni
(22)
,
Frederic Dezoteux
(23, 24)
,
Delphine Staumont-Salle
(23, 24)
,
Julien Bouleau
(23)
,
Pierre Labalette
(23)
,
Serge Doan
(25)
,
Angele Soria
(25)
,
Bruno Mortemousque
(26)
,
Julien Seneschal
(1)
,
Sebastien Barbarot
(2)
1
CHU Bordeaux -
Centre Hospitalier Universitaire de Bordeaux
2 PhAN - Physiopathologie des Adaptations Nutritionnelles
3 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
4 DMG Nantes - Département de médecine générale [Nantes Université - UFR de Médecine et des Techniques Médicales]
5 CHU Reims - Hôpital universitaire Robert Debré [Reims]
6 Hôpital Robert Debré
7 CHU Robert Debré
8 CardioVir - Infections Cardiovasculaires Virales et inflammation en pathologie humaine (CardioVir) UMR-S 1320
9 Université de Clermont-Ferrand
10 Service Ophtalmologie [CHU Clermont-Ferrand]
11 UCL - Université catholique de Lille
12 Service de Dermatologie [Nice]
13 CHU Nice - Centre Hospitalier Universitaire de Nice
14 Service de Dermatologie [Rouen]
15 Service de pneumologie, allergologie, mucoviscidose pédiatrique [Rouen]
16 ESCAPE - Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle
17 Service d'ophtalmologie [Rouen]
18 Infinity - Institut Toulousain des Maladies Infectieuses et Inflammatoires
19 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
20 CIRI - Centre International de Recherche en Infectiologie
21 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
22 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
23 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
24 INFINITE - Institute for Translational Research in Inflammation - U 1286
25 Hôpital Tenon Clermond-Ferrand
26 CIRID - Composantes innées de la réponse immunitaire et différenciation
2 PhAN - Physiopathologie des Adaptations Nutritionnelles
3 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
4 DMG Nantes - Département de médecine générale [Nantes Université - UFR de Médecine et des Techniques Médicales]
5 CHU Reims - Hôpital universitaire Robert Debré [Reims]
6 Hôpital Robert Debré
7 CHU Robert Debré
8 CardioVir - Infections Cardiovasculaires Virales et inflammation en pathologie humaine (CardioVir) UMR-S 1320
9 Université de Clermont-Ferrand
10 Service Ophtalmologie [CHU Clermont-Ferrand]
11 UCL - Université catholique de Lille
12 Service de Dermatologie [Nice]
13 CHU Nice - Centre Hospitalier Universitaire de Nice
14 Service de Dermatologie [Rouen]
15 Service de pneumologie, allergologie, mucoviscidose pédiatrique [Rouen]
16 ESCAPE - Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle
17 Service d'ophtalmologie [Rouen]
18 Infinity - Institut Toulousain des Maladies Infectieuses et Inflammatoires
19 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
20 CIRI - Centre International de Recherche en Infectiologie
21 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
22 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
23 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
24 INFINITE - Institute for Translational Research in Inflammation - U 1286
25 Hôpital Tenon Clermond-Ferrand
26 CIRID - Composantes innées de la réponse immunitaire et différenciation
Ingrid Costedoat
- Function : Author
- PersonId : 1295930
- ORCID : 0000-0003-1057-1010
Aurelie Gaultier
- Function : Author
- PersonId : 1228214
- IdHAL : aurelie-gaultier
- ORCID : 0000-0002-8266-1210
Marie Lamiaux
- Function : Author
- PersonId : 1295931
- ORCID : 0000-0002-7696-3511
Marie Tauber
- Function : Author
- PersonId : 756820
- ORCID : 0000-0001-6245-7442
- IdRef : 197536719
Audrey Nosbaum
- Function : Author
- PersonId : 793025
- ORCID : 0000-0003-2281-9052
- IdRef : 122796853
Marie Jachiet
- Function : Author
- PersonId : 786587
- ORCID : 0000-0001-5286-9689
Frederic Dezoteux
- Function : Author
- PersonId : 1226028
- ORCID : 0000-0001-8930-1042
Angele Soria
- Function : Author
- PersonId : 775956
- ORCID : 0000-0002-8726-6658
- IdRef : 131367218
Julien Seneschal
- Function : Author
- PersonId : 775154
- ORCID : 0000-0003-1139-0908
- IdRef : 129977373
Sebastien Barbarot
Connectez-vous pour contacter l'auteur
- Function : Correspondent author
- PersonId : 1202886
Connectez-vous pour contacter l'auteur
Abstract
Abstract Background Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination. Objective To examine the incidence, characteristics and risk factors of dupilumab‐induced ocular adverse events. Methods A prospective, multicenter, and real‐life study in adult AD patients treated with dupilumab. Results At baseline, 27 out of 181 patients (14.9%) had conjunctivitis. At week 16 (W16), 25 out of 27 had improved their conjunctivitis and 2 remained stable and 34 out of 181 patients (18.7%) had dupilumab‐induced blepharoconjunctivitis: either de novo ( n = 32) or worsening of underlying blepharoconjunctivitis ( n = 2). Most events (27/34; 79.4%) were moderate. A multivariate analysis showed that head and neck AD (OR = 7.254; 95%CI [1.938–30.07]; p = 0.004), erythroderma (OR = 5.635; 95%CI [1.635–21.50]; p = 0.007) and the presence of dry eye syndrome at baseline (OR = 3.51; 95%CI [3.158–13.90]; p = 0.031) were independent factors associated with dupilumab‐induced blepharoconjunctivitis. Limitations Our follow‐up period was 16 weeks and some late‐onset time effects may still occur. Conclusion This study showed that most dupilumab‐induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study.